英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
153902查看　153902　在百度字典中的解释百度英翻中〔查看〕
153902查看　153902　在Google字典中的解释Google英翻中〔查看〕
153902查看　153902　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home - Terns Pharma
    Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity
  • Merck to acquire Terns Pharmaceuticals for $6. 7B - Yahoo Finance
    Merck Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately
  • Merck to buy Terns Pharmaceuticals for about $6. 7B in cash | AP News
    Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6 7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years
  • Merck to buy Terns Pharmaceuticals for $6. 7 billion to boost . . . - CNBC
    Merck will acquire Terns for $53 per share in cash, amounting to an equity value of about $6 7 billion This is the third multibillion-dollar acquisition for Merck over the past year as it looks
  • Merck to Acquire Terns Pharmaceuticals in $6. 7 Billion Deal
    Merck amp; Co agreed to buy Terns Pharmaceuticals Inc for $6 7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its
  • Merck to Acquire Terns Pharmaceuticals, Inc. , Expanding Its Hematology . . .
    Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1 2 development for certain patients with CML Merck to hold investor call at 8 a m EDT today RAHWAY, N J and FOSTER CITY, Calif , March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc
  • Merck to Acquire Terns Pharmaceuticals for $6. 7 Billion, Expanding . . .
    Merck and Terns Pharmaceuticals announced a definitive agreement for Merck to acquire Terns for $53 00 per share, valued at approximately $6 7 billion This acquisition is seen as a strategic move to enhance Merck's presence in hematology through Terns’ investigational drug, TERN-701, an oral BCR::ABL1 tyrosine kinase inhibitor currently
  • Merck to Acquire Terns Pharmaceuticals, Inc. , Expanding Its Hematology . . .
    Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1 2 development for certain patients with CML M erck to hold investor call at 8 a m EDT today Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today
  • MSD to Acquire Terns Pharmaceuticals, Inc. , Expanding Its Hematology . . .
    Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines Terns’ lead program, TERN-701, is a highly selective, oral, allosteric BCR::ABL1 inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing
  • Merck nears $6 billion acquisition of Terns Pharma to boost cancer . . .
    Pharmaceutical company Merck is nearing a roughly $6 billion ‌all-cash deal to acquire biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter





中文字典-英文字典  2005-2009